O'Neill Gilmore Neil 4
4 · Editas Medicine, Inc. · Filed Mar 5, 2025
Insider Transaction Report
Form 4
O'Neill Gilmore Neil
DirectorCEO
Transactions
- Sale
Common Stock
2025-03-04$1.71/sh−16,632$28,452→ 295,474 total
Footnotes (2)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 3, 2025. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $1.7107 to $1.7125 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.